[HTML] from hematologylibrary.orgQ Jiang, LP Xu, DH Liu, KY Liu… - …, 2011 - bloodjournal.hematologylibrary.org The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) ... Related articles - All 6 versions
VS Nadarajan, CL Phan, CH Ang, KL Liang… - International journal of …, 2011 - Springer Abstract The outcome of treating chronic myeloid leu- kemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase. This may be attributed to additional genomic alterations that ... Cited by 1 - Related articles - All 3 versions
V Najfeld, N Wisch, J Mascarenhas, L Issa… - Cancer Genetics, 2011 - Elsevier ... Trisomy 8, double Ph, or other chromosomal abnormalities in lymphoid or myeloid cells are detected in patients in acceleratedphase or blast crisis CML, and specifically occur in descendents of clonal Ph + cells, consistent with a stepwise process. ... Related articles - All 3 versions
[HTML] from thelancet.comHM Kantarjian, A Hochhaus, G Saglio… - The Lancet …, 2011 - Elsevier ... 3 Significantly fewer patients on nilotinib progressed or transformed to acceleratedphase or blast phase than did patients on imatinib. 3 Here, we present updated results of the ENESTnd trial for patients with a minimum of 24 months of follow-up. Methods. Patients. ... Cited by 1
CA Eide, LT Adrian, JW Tyner, M Mac Partlin… - Cancer research, 2011 - AACR ... alone or with DCC-2036 (0.2–3,125 nmol/L) or imatinib (0.2–3,125 nmol/L) as described (8). For primary cell experiments, following informed consent, peripheral blood mononuclear cells from a newly diagnosed CML patient and from an acceleratedphase patient harboring ... Cited by 2 - Related articles - All 4 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
